Athira Pharma logo

Athira PharmaNASDAQ: ATHA

Profile

Sector:

Healthcare

Industry:

Biotechnology

Country:

United States

IPO:

18 September 2020

Next earnings report:

08 November 2024

Last dividends:

N/A

Next dividends:

N/A
$23.25 M
-96%vs. 3y high
26%vs. sector
-vs. 3y high
-vs. sector
-84%vs. 3y high
22%vs. sector
-vs. 3y high
-vs. sector

Price

after hours | Fri, 01 Nov 2024 23:59:59 GMT
$0.60+$0.04(+8.00%)

Dividend

No data over the past 3 years
No data over the past 3 years

Analysts recommendations

Institutional Ownership

ATHA Latest News

ATHA Energy appoints seasoned experts to leadership team
proactiveinvestors.com29 October 2024 Sentiment: POSITIVE

ATHA Energy Corp (CSE:SASK, OTCQB:SASKF) has announced the appointment of Erinn Broshko as a non-executive director and Rhéal Assié as chief financial officer, starting November 6. The company said Broshko, a seasoned executive and lawyer, brings more than 25 years of experience in law, business, and leadership, including roles as CEO and executive chairman in biotech and energy services.

ATHA Energy and Terra Uranium enter into strategic option agreements on key uranium projects
proactiveinvestors.com11 October 2024 Sentiment: POSITIVE

ATHA Energy Corp (CSE:SASK, OTCQB:SASKF) announced that it has entered into option agreement with Terra Uranium Ltd (ASX:T92) which allow the two companies to earn significant interest in each other's uranium exploration projects. ATHA has granted Terra Uranium an option to acquire up to 70% interest in its Spire and Horizon properties, together the Spire Horizon projects.

ATHA Energy secures entire Lac 50 structural corridor at Angilak uranium project
proactiveinvestors.com19 September 2024 Sentiment: POSITIVE

ATHA Energy Corp (CSE:SASK, OTCQB:SASKF) has expanded its Angilak Project in Nunavut by acquiring the entire Lac 50 structural corridor, along with an additional prospective parallel corridor. Both corridors are linked to the Snowbird Tectonic Zone, a significant crustal structure that extends from the Athabasca Basin to the Angikuni Basin.

Athira Pharma laying off 49 employees, about 70% of workforce, as part of restructuring
geekwire.com17 September 2024 Sentiment: NEGATIVE

Seattle-based biotech company Athira Pharma is laying off 49 people, or about 70% of its workforce, as part of cost-cutting measures and a restructuring.

Athira Pharma to Focus on Advancement of ATH-1105 for the Treatment of Neurodegenerative Diseases
globenewswire.com17 September 2024 Sentiment: POSITIVE

ATH-1105 is an orally delivered, positive modulator of the neurotrophic HGF system that is currently in a Phase 1 clinical trial with completion expected by year end 2024 and commencement of dosing of ALS patients expected in 2025

ATHA Stock Tanks as Alzheimer's Study Fails to Meet Primary Goal
zacks.com04 September 2024 Sentiment: NEGATIVE

Athira's phase II/III LIFT-AD study on fosgonimeton for treating mild-to-moderate Alzheimer's disease fails to meet primary and secondary endpoints.

ATHA Energy identifies new mineralized trends at Angilak uranium project
proactiveinvestors.com03 September 2024 Sentiment: POSITIVE

ATHA Energy Corp (CSE:SASK, OTCQB:SASKF) announced it has completed its 2024 Exploration Program at its Angilak uranium project in Nunavut, which hosts the Lac 50 uranium Deposit. The “highly successful” program was carried out from early June to late August and involved 25 diamond drill holes totalling about 10,051 meters.

ATHA Energy advances exploration at Gemini and Angilak uranium projects
proactiveinvestors.com28 August 2024 Sentiment: POSITIVE

ATHA Energy Corp (CSE:SASK, OTCQB:SASKF) has provided investors with an update on its 2024 exploration programs at its uranium projects. At its Gemini project in the Athabasca Basin, Saskatchewan, the company in late August kicked off a Phase 3 diamond drill program to expand the footprint of mineralization, targeting the down-dip extents of the Gemini Mineralized Zone (GMZ).

ATHA Energy Announces Proposed Option Agreements with Terra Uranium for Spire, Horizon, and Pasfield Projects
globenewswire.com20 August 2024 Sentiment: POSITIVE

VANCOUVER, British Columbia, Aug. 20, 2024 (GLOBE NEWSWIRE) -- ATHA Energy Corp. (TSXV: SASK) (FRA: X5U) (OTCQB: SASKF) (“ATHA”) is pleased to announce that it has entered into a non-binding letter of intent (the “LOI”) with Terra Uranium Ltd. (ASX: T92) (“T92”), whereby the parties will work to negotiate a definitive option and joint venture agreement for T92 to earn an option to acquire a 70% interest in ATHA's Spire and Horizon properties (together, the “Spire Horizon Projects”) and a definitive option and joint venture agreement for ATHA to earn an option to acquire up to a 60% interest in T92's Pasfield Lake property (the “Pasfield Project”).

Athira Pharma Reports Second Quarter 2024 Financial Results and Pipeline and Business Updates
globenewswire.com01 August 2024 Sentiment: POSITIVE

Topline data from completed Phase 2/3 LIFT-AD clinical trial of fosgonimeton as a potential treatment for mild-to-moderate Alzheimer's disease targeted for September 2024 Phase 2/3 LIFT-AD data to be presented in an oral presentation at CTAD in October 2024 Phase 1 clinical trial of ATH-1105 underway for the potential treatment of amyotrophic lateral sclerosis (ALS) BOTHELL, Wash., Aug. 01, 2024 (GLOBE NEWSWIRE) -- Athira Pharma, Inc. (NASDAQ: ATHA), a late clinical-stage biopharmaceutical company focused on developing small molecules to restore neuronal health and slow neurodegeneration, today reported financial results for the quarter ended June 30, 2024, and provided recent pipeline and business updates.

  • 1(current)

What type of business is Athira Pharma?

Athira Pharma, Inc., a late clinical-stage biopharmaceutical company, focuses on developing small molecules to restore neuronal health and slow neurodegradation. Its lead product candidate is Fosgonimeton (ATH-1017), a small molecule designed to modulate the neurotrophic hepatocyte growth factor (HGF) system and its receptor, MET, for a healthy nervous system that is in LIFT-AD Phase 2/3 and ACT-AD Phase 2 clinical trials for the treatment of Alzheimer's disease, as well as is in Phase 2 clinical trials to treat Parkinson's disease dementia and Dementia with Lewy bodies. The company's product pipeline includes ATH-1020, an orally available brain-penetrant small molecule designed to enhance the HGF/MET system that is in Phase 1 clinical trials to treat neuropathic pain and neurodegenerative diseases; and ATH-1105, an oral small molecule drug candidate, which is a preclinical model for the treatment of Amyotrophic Lateral Sclerosis. In addition, it has a license agreement with Washington State University to offer for sale products covered by certain licensed patents, including dihexa, the chemical compound into which fosgonimeton metabolizes following administration; and collaboration and grant agreement with National Institutes of Health Grant to support ACT-AD Phase 2 clinical trial for fosgonimeton. The company was formerly known as M3 Biotechnology, Inc. and changed its name to Athira Pharma, Inc. in April 2019. Athira Pharma, Inc. was incorporated in 2011 and is headquartered in Bothell, Washington.

What sector is Athira Pharma in?

Athira Pharma is in the Healthcare sector

What industry is Athira Pharma in?

Athira Pharma is in the Biotechnology industry

What country is Athira Pharma from?

Athira Pharma is headquartered in United States

When did Athira Pharma go public?

Athira Pharma initial public offering (IPO) was on 18 September 2020

What is Athira Pharma website?

https://www.athira.com

Is Athira Pharma in the S&P 500?

No, Athira Pharma is not included in the S&P 500 index

Is Athira Pharma in the NASDAQ 100?

No, Athira Pharma is not included in the NASDAQ 100 index

Is Athira Pharma in the Dow Jones?

No, Athira Pharma is not included in the Dow Jones index

When was Athira Pharma the previous earnings report?

No data

When does Athira Pharma earnings report?

The next expected earnings date for Athira Pharma is 08 November 2024